Skip to main content

Table 1 Subject characteristics

From: Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adults

Group:

E

A

B

C

D

Characteristic

Placebo N = 60

60 μg + Al N = 40

60 μg N = 40

90 μg + Al N = 40

90 μg N = 40

Gender, n (%)

 Male

22 (37)

18 (45)

16 (40)

21 (53)

17 (43)

 Female

38 (63)

22 (55)

24 (60)

19 (48)

23 (58)

Race, n (%)

 White or Caucasian

58 (97)

40 (100)

39 (98)

37 (93)

40 (100)

 Black or African American

1 (2)

0

0

3 (8)

0

 Asian

0

0

0

0

0

 American Indian/Alaska Native

0

0

0

0

0

 Native Hawaiian/Other Pacific Islander

0

0

0

0

0

 Other

1 (2)

0

1 (3)

0

0

Ethnicity, n (%)

 Hispanic or Latino

0

0

1 (3)

2 (5)

3 (8)

 Not Hispanic or Latino

60 (100)

40 (100)

39 (98)

38 (95)

37 (93)

Age Group (years), n (%)

 60 to < 75

51 (85)

34 (85)

34 (85)

34 (85)

34 (85)

  ≥ 75

9 (15)

6 (15)

6 (15)

6 (15)

6 (15)

Age (years)

 n

60

40

40

40

40

 Mean (SD)

69.1 (5.5)

69.1 (5.8)

67.7 (5.6)

68.0 (5.8)

68.7 (5.7)

 Median

68.0

68.0

67.0

68.0

68.0

 Min, Max

60, 87

60, 83

60, 85

60, 85

61, 81

  1. Percentages are based on the number of subjects in the Safety Population with non-missing data within treatment group
  2. Age is calculated as the closest integer result of (Date of Study day 0 – Date of Birth)/365.25